Redeye highlights its key assumptions ahead of the Q3 report, due 9 November.
Redeye updates our outlook after Q3. XVIVO delivers a improved gross and EBITDA margins and an overa...
51% beat on EBITDA in Q3 New strategy and mid-term financial targets Earnings revised up for '23e, b...
Q3e: 27% y-o-y ARR growth, adj. EBITDA of DKK -4.9m Decent Q3 despite seasonality headwinds; still n...
Norway and Denmark are steaming ahead... ...more than offsetting the weaker Sweden Profitability com...
Redeye lowers its estimates for the Q3 report which is due on Friday.
Sales +1% vs. ABGSCe, EBIT +50% on lower opex Outlook: expects the weak market to linger in the near...
Redeye briefly comments on Annexin Pharmaceuticals rights issue.
Redeye updates its view on Acconeer ahead of the Q3 report (due 27 October).
Q3 7% organic growth and $36m (+1-8% vs expectations) 2023 Guidance unchanged, very wide implicit Q4...
Innofactor’s Q3 results were good and quite as expected despite market headwinds.
Low ICR in 2024e... ...but we see supportive options 2024e P/CEPS at ~13.
We incorporate the MFG divestment... ...which pushes CEPS up by ~30%.
Atria reported Q3 EBIT of EUR 19.3m, 28% (EUR 4.2m) above Refinitiv consensus.
Redeye comments on the first data from the ATLAS-IT-05 trial, a study of the oncolytic molecule LTX-...
Redeye judges that more mature NIPU data, indicating OS and ORR benefits of UV1 addition to double C...
Kvartalsrapporten visar högre hyresintäkter och upprätthållet förvaltningsresultat.
OrderYOYO A/S (“OrderYOYO” or the “Company”) continued the Company’s strong performance in Q3-23, sh...
Redeye comments on the new positive results in triple-negative breast cancer presented at ESMO this ...
Redeye provides a quick comment on Gasporox’s AutoMap agreement worth SEK3m with Weber Maschinenbau ...
